文献速递乳腺癌

新辅助治疗联合或不联合阿替利珠单抗治疗三阴性早期高危和局部晚期乳腺癌的病理完全缓解:NeoTRIP Michelangelo随机研究

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
PubMed 文献 · Ann Oncol · 2022-02-17

这项多中心随机研究纳入280例三阴性乳腺癌患者,比较新辅助卡铂联合白蛋白结合型紫杉醇联合或不联合阿替利珠单抗的疗效。意向治疗分析显示,联合阿替利珠单抗组病理完全缓解率为48.6%,未联合组为44.4%,差异无统计学意义(OR 1.18,95%CI 0.74-1.89,P=0.48)。联合阿替利珠单抗组严重不良事件和肝转氨酶异常总体发生率显著更高。

要点

  • 联合阿替利珠单抗组病理完全缓解率为48.6%,未联合组为44.4%,差异无统计学意义(OR 1.18,95%CI 0.74-1.89,P=0.48)。
  • 联合阿替利珠单抗组严重不良事件和肝转氨酶异常的总体发生率显著更高。
  • 多因素分析中,PD-L1表达是影响病理完全缓解率的最显著因素(OR 2.08)。

核心结论

  • 在卡铂联合白蛋白结合型紫杉醇的新辅助治疗中加入阿替利珠单抗,未显著提高三阴性乳腺癌女性的病理完全缓解率。
  • 多因素分析中,PD-L1表达是影响病理完全缓解率的最显著因素(OR 2.08)。
  • 无事件生存期的随访仍在进行中,分子研究正在进行中。

研究设计与样本

  • 多中心随机研究(NCT002620280),纳入280例三阴性乳腺癌患者。
  • 患者随机接受新辅助卡铂(曲线下面积2)联合白蛋白结合型紫杉醇125 mg/m2静脉注射(第1天和第8天),不联合阿替利珠单抗组142例,联合阿替利珠单抗1200 mg静脉注射(第1天)组138例。
  • 两种方案均每3周给药一次,共8个周期,术后接受4个周期辅助蒽环类方案。
  • 主要目的为比较无事件生存期,重要次要目的为病理完全缓解率(定义为乳腺和淋巴结中无浸润性细胞)。
  • 所有疗效终点的主要分析人群为意向治疗人群。

主要发现

  • 意向治疗分析显示,联合阿替利珠单抗组病理完全缓解率为48.6%,未联合组为44.4%,差异未达统计学显著(OR 1.18,95%CI 0.74-1.89,P=0.48)。
  • 两种方案的治疗相关不良事件相似,但联合阿替利珠单抗组严重不良事件和肝转氨酶异常的总体发生率显著更高。
  • 多因素分析中,PD-L1表达是影响病理完全缓解率的最显著因素(OR 2.08)。

关键数值与推荐

  • 病理完全缓解定义为乳腺和淋巴结中无浸润性细胞。
  • 联合阿替利珠单抗组病理完全缓解率为48.6%,未联合组为44.4%(OR 1.18,95%CI 0.74-1.89,P=0.48)。
  • 多因素分析中PD-L1表达影响病理完全缓解率的OR为2.08。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy, thus representing an area in need of new therapeutic approaches. Programmed death-ligand 1 (PD-L1) expression is an adaptive mechanism of tumour resistance to tumour-infiltrating lymphocytes, which in turn are needed for response to chemotherapy. Overall, available data support the concept that blockade of PD-L1/programmed cell death protein 1 checkpoint may improve efficacy of classical chemotherapy. PATIENTS AND METHODS: Two hundred and eighty patients with TNBC were enrolled in this multicentre study (NCT002620280) and randomized to neoadjuvant carboplatin area under the curve 2 and nab-paclitaxel 125 mg/m2 intravenously (i.v.) on days 1 and 8, without (n = 142) or with (n = 138) atezolizumab 1200 mg i.v. on day 1. Both regimens were given q3 weeks for eight cycles before surgery followed by four cycles of an adjuvant anthracycline regimen. The primary aim of the study was to compare event-free survival (EFS), and an important secondary aim was the rate of pathological complete response (pCR defined as the absence of invasive cells in breast and lymph nodes). The primary population for all efficacy endpoints is the intention-to-treat (ITT) population. RESULTS: The ITT analysis revealed that pCR rate after treatment with atezolizumab (48.6%) did not reach statistical significance compared to no atezolizumab [44.4%: odds ratio (OR) 1.18; 95% confidence interval 0.74-1.89; P = 0.48]. Treatment-related adverse events were similar with either regimen except for a significantly higher overall incidence of serious adverse events and liver transaminase abnormalities with atezolizumab. CONCLUSIONS: The addition of atezolizumab to nab-paclitaxel and carboplatin did not significantly increase the rate of pCR in women with TNBC. In multivariate analysis, the presence of PD-L1 expression was the most significant factor influencing the rate of pCR (OR 2.08). Continuing follow-up for the EFS is ongoing, and molecular studies are under way.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022. PMID: 35182721. doi:10.1016/j.annonc.2022.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。